期刊文献+

大鼠血浆中7-乙基-10-羟基喜树碱-10-棕榈酸酯及7-乙基-10-羟基喜树碱HPLC分析方法的建立

Establishment of HPLC method for determination of SN38-PA and SN38 in rat plasma
下载PDF
导出
摘要 目的建立同时测定大鼠血浆中7-乙基-10-羟基喜树碱-10-棕榈酸酯(SN38-PA)及其活性代谢产物7-乙基-10-羟基喜树碱(SN38)含量的高效液相色谱法。方法以10-羟基喜树碱(10-CPT)作为内标,甲酸酸化血浆,甲醇沉淀蛋白。采用Agilent C18柱(4.6 mm×250 mm,5μm)色谱柱,以甲醇-0.2%甲酸水溶液为流动相进行梯度洗脱,流速1 ml/min,紫外检测波长372 nm,柱温:30℃。结果大鼠血浆中SN38-PA和SN38线性范围分别为0.25--62.5(r=0.9998)和0.05--12.5μg/ml(r=0.9997),最低定量限分别为0.18和0.04μg/ml;两组分平均绝对回收率分别为95.89%和97.03%;平均相对回收率分别为99.54%和99.84%。2组分日内、日间精密度的RSD%均〈3%。结论本分析方法快速、简便、准确度和灵敏度高,可用于SN38-PA及其活性代谢产物SN38的体内检测。 Objective To develop an HPLC method for the simultaneous determination of 7-ethyl-10-hydroxycamptothecin-10-palmitic acid ester(SN38-PA)and its active metabolite 7-ethyl-10-hydroxycamptothecin(SN38)in rat plasma. Methods The inter standard was 10-hydroxycamptothecin. The protein in plasma was precipitated with methanol after acidification with formic acid.SN38-PA and SN38 were separated on Agilent C18column(4.6 mm×250 mm,5 μm)with gradient elution by using the mobile phase of methanol-0.2% formic acid solution. The flow rate was 1 ml/min. The detection wavelength was set at 372 nm. The column temperature was maintained at 30℃. Results The linear ranges for SN38-PA and SN38 were 0.25-62.5(r=0.9998) and 0.05-12.5 μg/ml(r =0.9997) respectively. The limits of quantification were 0.18 and 0.04 μg/ml,respectively. The average relative recovery of SN38-PA and SN38 were 95.89% and 97.03%. The average absolutely recovery of SN38-PA and SN38 were 99.54% and99.84%. The RSD for intra-day and inter-day were both less than 3%. Conclusion The method is fast,convenient,accurate and sensitive,so it can be used for determination of SN38-PA and SN38 in vivo.
出处 《国际药学研究杂志》 CAS CSCD 北大核心 2015年第5期646-649,共4页 Journal of International Pharmaceutical Research
关键词 高效液相色谱法 SN38-PA SN38 含量测定 HPLC SN38-PA SN38 quantitative analysis
  • 相关文献

参考文献9

  • 1Meyer-Losic F, Nicolazzi C, Quinonero J, et al. DTS-108, a novel peptidic prodrug of SN38: in vivo efficacy and toxicokinetic studies[J]. Clin Cancer Res, 2008, 14(7): 2145-2153.
  • 2郭晓鹏,冯思良,王金辉,俞腾飞.拓扑异构酶1及其喜树碱类抑制剂的临床研究进展[J].国际药学研究杂志,2013,40(4):405-414. 被引量:21
  • 3Zhang JA, Xuan T, Parmar M, et al. Development and char-acterization of a novel liposome-based formulation of SN-38[J]. Int J Pharm, 2004, 270(1/2): 93-107.
  • 4Marier JF, Pheng L, Trinh MM, et al. Pharmacokinetics of SN2310, an injectable emulsion that incorporates a new derivative of SN-38 in patients with advanced solid tumors[J]. J Pharm Sci, 2011, 100(10): 4536-4545.
  • 5Roger E, Lagarce F, Benoit J P. Development and characteri-zation of a novel lipid nanocapsule formulation of SN38 for oral administration[J]. Eur J Pharm Biopharm, 2011, 79(1): 181-188.
  • 6吕 伟,何训贵,章雄文,等. 羟基喜树碱及其衍生物的羧酸酯前药、其制备方法与应用:中国,200410017128.5[P]. 2005-9-28.
  • 7Takayama H, Watanabe A, Hosokawa M, et al. Synthesis of a new class of camptothecin derivatives, the long-chain fatty acid esters of 10-hydroxycamptothecin, as a potent prodrug candidate, and their in vitro metabolic conversion by carboxylesterases[J]. Bioorg Med Chem Lett, 1998, 8(5): 415-418.
  • 8Jeong W, Park SR, Rapisarda A, et al. Weekly EZN-2208 (PEGylated SN-38) in combination with bevacizumab in patients with refractory solid tumors[J]. Invest New Drugs, 2014, 32(2): 340-346.
  • 9刘东,高静,张程亮,向道春,高萍.高效液相色谱法测定大鼠血浆中伊立替康及其活性代谢产物SN-38的含量[J].药物分析杂志,2011,31(4):625-628. 被引量:6

二级参考文献61

  • 1Namkoong EM,Kim IW,Kim DD,et al.Effect of probenecid on the biliary excretion of belotecan.Arch Pharm Res,2007,30(11):1482.
  • 2Namkoong EM, Kim IW, Kim DD,et al. Effect of probenecid on the biliary excretion of belotecan. Arch Pharm Res ,2007,30( 11 ) : 1482.
  • 3Takemoto I,Itagaki S,Chiba M,et al.Characterization of secretory intestinal transport of the lactone form of CPT-11.Cancer Chemother Pharmacol,2006,57(1):129.
  • 4Owens TS,Dodds H,Fricke K,et al.High-performance liquid chromatographic assay with fluorescence detection for the simultaneous measurement of carboxylate and lactone forms of irinotecan and three metabolites in human plasma.J Chromatogr B Analyt Technol Biomed Life Sci,2003,788(1):65.
  • 5De Bruijn P,Verweij J,Loos WJ,et al.Determination of irinotecan (CPT-11) and its active metabolite SN-38 in human plasma by reversed-phase high-performance liquid chromatography with fluorescence detection.J Chromatogr B Biomed Sci Appl,1997,698(1-2):277.
  • 6Yang X,Hu Z,Chan SY,et al.Simultaneous determination of the lactone and carboxylate forms of irinotecan (CPT-11) and its active metabolite SN-38 by high-performance liquid chromatography: application to plasma pharmacokinetic studies in the rat.J Chromatogr B Analyt Technol Biomed Life Sci,2005,821(2):221.
  • 7Poujol S,Pinguet F,Malosse F,et al.Sensitive HPLC-fluorescence method for irinotecan and four major metabolites in human plasma and saliva: application to pharmacokinetic studies.Clin Chem,2003,49(11):1900.
  • 8Sumiyoshi H,Fujiwara Y,Ohune T,et al.High-performance liquid chromatographic determination of irinotecan (CPT-11) and its active metabolite (SN-38) in human plasma.J Chromatogr B Biomed Appl,1995,670(2):309.
  • 9Pommier Y, Leo E, Zhang H, et al. DNA topoisomerases and their poisoning by anticancer and antibacterial drugs [ J ]. Chem Biol, 2010, 17(5) :421433.
  • 10Tomieic MT, Kaina B. Topoisomerase degradation, DSB repair, p53 and IAPs in cancer cell resistance to camptotheein-like topoi- somerase I inhibitors[ J ]. Biochim Biophys, 2013, 1835 ( 1 ) : 11-27.

共引文献25

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部